
Pfizer has received a bittersweet bout of news as it emerges that its drug Besponsa (inotuzumab ozogamicin) has received approval …

It was a case of three-in-one bits of good news for AstraZeneca and MSD, after the FDA boosted the newly …

Newcastle upon Tyne Hospital’s Chief Executive, Leonard Fenwick, has been sacked from his position after a disciplinary panel adjudged he …

British Heart Foundation’s Jennifer Mitchell, Research Communications Officer, explains the work they are doing to find the next breakthrough treatment …

Immunotherapy treatments that focus on the PD-L1 protein have become some of the most exciting to emerge in cancer treatment. …

The FDA has announced that it has been forced to recall a range of liquid pharmaceutical and dietary supplement products …

Soliris brought in net sales of $2.8 billion last year for Alexion, meaning it accounted for close to 90% of …

Novo Nordisk has revealed that its diabetes drug semaglutide managed to outperform Eli Lilly’s own treatment dulaglutide (Trulicity) in controlling …

Cancer Research UK and Newcastle University have announced that their existing research collaboration with Astex Pharmaceuticals will be extended for …

A team of researchers at Stanford University have engineered a new, highly-sensitive molecular test to detect and monitor cancer which …

A study emerging from Newcastle University has pointed towards a potential crisis in care home places by 2025, as a …

Bristol-Myers Squibb has been left somewhat red-faced after its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) failed to show any …

A study emerging from St George’s University of London found that children who slept an hour less than the recommended …

A team of researchers from the University of Toronto have confronted a problem that had previously had no solution – …

This month has seen two new additions to Novo Nordisk’s Executive Management team. First of the pair is Camila Sylvest, …

Shire has announced that it has submitted its dry-eye drug, lifitegrast, for European marketing approval. The filing comes after it …

Gilead is set for the grand unveiling of its new facility in La Verne, Southern California, after several years of …

Regeneron has announced that the failure of suptavumab, its experimental treatment for respiratory syncytial virus (RSV), in late-stage trials, the …

A small biotech that has been working on developing one treatment for the last decade has finally seen the fruits …

In a shock move, MSD Chairman and Chief Executive Officer Kenneth Frazier (pictured) has announced that he is to resign …